During the first day of the SMi Biosimilars Meeting held in Iselin, New Jersey, from November 14-15, 2018, Christina Yunis, global biosimilars market development lead at Pfizer, discussed the sustainability of and challenges seen in the biosimilars market from an industry perspective.
During the first day of the SMi Biosimilars Meeting held in Iselin, New Jersey, from November 14-15, 2018, Christina Yunis, global biosimilars market development lead at Pfizer, discussed the sustainability of and challenges seen in the biosimilars market from an industry perspective.
“Approval is only 1 challenge, then there are the differences seen in the regulatory perspectives provided by the FDA versus the [European Union], patent challenges, building provider and patient confidence, and battling misinformation,” said Yunis.
While various government agencies, such as HHS and the FDA, have put out documents looking to answer questions about driving biosimilar uptake, more still needs to be done. Yunis echoed what much of the marketplace deems as the ultimate goal of the biosimilar market: achieving long-term sustainability.
As of today, there are 14 biosimilars approved in the United States, though only 6 are available on the market with Pfizer’s epoetin alfa biosimilar, Retacrit, being the latest product, announced the morning of Yunis' presentation.
“Before achieving long-term sustainability, we need to first discuss the state of the market today. There are many hurdles to overcome­—contracting and intellectual property hurdles, regulatory and legal challenges, lack of clinical experience, pricing and reimbursement challenges, and misinformation in the marketplace,” said Yunis.
One of the main challenges that Yunis finds surprising is the many different insurance coverage plans that exist that either do not cover a biosimilar or only cover the biosimilar after a patient has failed on the reference product.
“When you think of the medical perspective, why on earth would you prescribe a biosimilar to a patient that failed on the reference product? This is clearly blocking coverage of the biosimilar,” she said. In fact, this is a common condition listed in some insurance plans, and is an issue going through the courts today as seen in Pfizer v. Johnson and Johnson.
Around challenging information in the marketplace, Yunis explained that when there’s a lot of confusion, physicians go back to what they know. For its part, the FDA has recognized this confusion and looked to address it through various education efforts such as educational videos, pamphlets, and documents.
However, sometimes too much information can be overwhelming. “One of the challenges we’re seeing now is information overload. I was in a meeting last week with some patient advocacy groups that told us that, it’s not that they didn’t have enough information, it’s that they had too much,” she said. To counteract this, Yunis said that we need to make it simple, with a reliable source of information where patients and providers alike can go and make informed decisions.
Although she conceded that she may not have the final solution, she believes “we have a responsibility to address the misinformation in the market, and instead maintain a consistent message across the board.”
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars
May 2nd 2024Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Dr Sophia Humphreys Provides Calls to Action to Ensure Biosimilar Market Sustainability
April 30th 2024During her presentation during Festival of Biologics USA, Sophia Humphreys, PharmD, director of formulary management at Sutter Health, gave an overview of current challenges and opportunities for the biosimilar market and offered calls to action for multiple stakeholders.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.